Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$204.41 USD

204.41
290,642

-1.09 (-0.53%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $204.41 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Penumbra (PEN) Down 2.1% Since Last Earnings Report?

by Zacks Equity Research

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Up (Revised)

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation, and improved underlying fundamentals contributes to Medtronic (MDT) Q1 revenues.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strength across businesses and geographies, driven by execution, innovation and improved underlying fundamentals, contributes to Medtronic's (MDT) Q1 revenues.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are upbeat about Penumbra (PEN) on Strong uptake following the launch of Lightning Flash, which accelerated top-line growth.

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

by Zacks Equity Research

Strength across all businesses is likely to drive Medtronic's (MDT) first-quarter performance.

TransMedics (TMDX) Acquires Summit Aviation for Organ Transplant

by Zacks Equity Research

TransMedics' (TMDX) acquisition of Summit Aviation is likely to help establish TransMedics Aviation, the first integrated national provider of air logistics dedicated exclusively to organ transplantation.

Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind

by Zacks Equity Research

Phibro (PAHC) input costs continue to be high as a result of sustained inflation.

Neogen (NEOG) Introduces New Genomic Data Management Tool

by Zacks Equity Research

Neogen's (NEOG) new Igenity Enhanced Dairy offers farmers valid data and assesses their herd's potential. It helps them make the most informed decisions.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) continued growth across the insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Thermo Fisher (TMO) Completes the CorEvitas Acquisition

by Zacks Equity Research

Thermo Fisher's (TMO) latest buyout is likely to deliver $0.03 in adjusted earnings per share in 2024 and be marginally accretive in 2023.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of a solid foundation for innovative therapies.

Shaun Pruitt headshot

Time to Buy These Medical Stocks as Earnings Approach

by Shaun Pruitt

Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.

HCA Healthcare (HCA) Rises 24% in a Year: More Room to Run?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of improved patient occupancy levels, effective telehealth services suite and solid cash-generating abilities.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on its strategic expansion in the global market and recovery within the Nutrition segment.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and acquisitions.

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

by Zacks Equity Research

Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications.

Here's Why You Should Invest in Alcon (ALC) Stock Now

by Zacks Equity Research

Investors are optimistic about Alcon (ALC) owing to its strength in Surgical and Vision Care franchises and upbeat 2023 guidance.

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.

Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up

by Zacks Equity Research

The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

by Zacks Equity Research

QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.

Here's Why You Should Invest in Medtronic (MDT) Stock Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

by Zacks Equity Research

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.

National Vision (EYE) Gains From Store Openings Amid Cost Woes

by Zacks Equity Research

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.

Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y

by Zacks Equity Research

Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.